机构:[1]Department of Clinical Laboratory Medicine and.[2]Faculty of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.[3]Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China; and.医技科室职能科室临床流行病与循证医学中心血液中心首都医科大学附属北京儿童医院[4]Clinical Research Center, Ruijin Hospital, and.[5]Collaborative Innovation Center of Hematology, Shanghai Jiaotong University School of Medicine, Shanghai, China.
第一作者机构:[1]Department of Clinical Laboratory Medicine and.[2]Faculty of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
推荐引用方式(GB/T 7714):
Lu Yeling,Chen Zhenping,Dai Jing,et al.Maternal microchimerism protects hemophilia A patients from inhibitor development.[J].Blood advances.2020,4(9):1867-1869.doi:10.1182/bloodadvances.2020001832.
APA:
Lu Yeling,Chen Zhenping,Dai Jing,Wu Xi,Gu Hao...&Wang Xuefeng.(2020).Maternal microchimerism protects hemophilia A patients from inhibitor development..Blood advances,4,(9)
MLA:
Lu Yeling,et al."Maternal microchimerism protects hemophilia A patients from inhibitor development.".Blood advances 4..9(2020):1867-1869